Haleon plc (HLN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Haleon plc stock (HLN) is currently trading at $10.23. Haleon plc PE ratio is 21.04. Haleon plc PS ratio (Price-to-Sales) is 4.16. Analyst consensus price target for HLN is $12.09. WallStSmart rates HLN as Hold.
- HLN PE ratio analysis and historical PE chart
- HLN PS ratio (Price-to-Sales) history and trend
- HLN intrinsic value — DCF, Graham Number, EPV models
- HLN stock price prediction 2025 2026 2027 2028 2029 2030
- HLN fair value vs current price
- HLN insider transactions and insider buying
- Is HLN undervalued or overvalued?
- Haleon plc financial analysis — revenue, earnings, cash flow
- HLN Piotroski F-Score and Altman Z-Score
- HLN analyst price target and Smart Rating
Haleon
📊 No data available
Try selecting a different time range
HLN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Haleon plc (HLN)
HLN trades at a significant discount to its Graham intrinsic value of $22.93, offering a 51% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Haleon plc (HLN) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, operating margin, eps growth. Concerns around revenue growth and institutional own.. Fundamentals are solid but monitor weak areas for improvement.
Haleon plc (HLN) Key Strengths (4)
Earnings per share surging 92.00% year-over-year
Large-cap company with substantial market presence
Strong operational efficiency: $23 kept per $100 revenue
Strong profitability: $15 kept per $100 revenue
Supporting Valuation Data
Haleon plc (HLN) Areas to Watch (6)
Revenue growing slowly at 0.60% annually
Very low institutional interest at 12.73%
Paying a premium for growth, expensive relative to earnings expansion
Premium valuation at 4.2x annual revenue
Moderate profitability with room for improvement
Fairly priced relative to book value
Haleon plc (HLN) Detailed Analysis Report
Overall Assessment
This company scores 58/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.8/10) while 6 fall into concern territory (avg 3.8/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on EPS Growth, Market Cap, Operating Margin. Profitability is solid with Operating Margin at 23.20%, Profit Margin at 15.10%. Growth metrics are encouraging with EPS Growth at 92.00%.
The Bear Case
The primary concerns are Revenue Growth, Institutional Own., PEG Ratio. Some valuation metrics including PEG Ratio (2.48), Price/Sales (4.16), Price/Book (2.17) suggest expensive pricing. Growth concerns include Revenue Growth at 0.60%, which may limit upside. Profitability pressure is visible in Return on Equity at 10.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 10.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 0.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (EPS Growth, Market Cap) and negatives (Revenue Growth, Institutional Own.). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
WallStSmart Analysis Synopsis
Data-driven financial summary for Haleon plc (HLN) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Haleon plc is a strong growth company balancing expansion with improving profitability. Revenue reached 11.0B with 60% growth year-over-year. Profit margins of 15.1% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 60% YoY, reaching 11.0B. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
ROE of 1030.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Haleon plc maintain 60%+ revenue growth, or will competition slow it down?
Debt management: total debt of 8.5B is significantly higher than cash (676M). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Haleon plc.
Bottom Line
Haleon plc offers an attractive blend of growth (60% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 5:46:24 AM
About Haleon plc(HLN)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.